Daud AI - Search Results

1

Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.

Marchion DC, Bicaku E, Turner JG, Daud AI, Sullivan DM, Munster PN. Marchion DC, et al. Among authors: daud ai. Clin Cancer Res. 2005 Dec 1;11(23):8467-75. doi: 10.1158/1078-0432.CCR-05-1073. Clin Cancer Res. 2005. PMID: 16322310

2

Purification and characterization of a novel 35-kDa protein from transformed cardiomyocytes.

Chandrasekhar S, Münster PN, Henzel WA, Daud AI. Chandrasekhar S, et al. Among authors: daud ai. Cell Biol Int. 1999;23(4):299-306. doi: 10.1006/cbir.1998.0328. Cell Biol Int. 1999. PMID: 10600238

3

New drugs in gynecologic cancer.

Daud A, Munster P, Munster P, Spriggs DR. Daud A, et al. Curr Treat Options Oncol. 2001 Apr;2(2):119-28. doi: 10.1007/s11864-001-0054-0. Curr Treat Options Oncol. 2001. PMID: 12057130 Review.

4

Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid.

Marchion DC, Bicaku E, Daud AI, Richon V, Sullivan DM, Munster PN. Marchion DC, et al. Among authors: daud ai. J Cell Biochem. 2004 May 15;92(2):223-37. doi: 10.1002/jcb.20045. J Cell Biochem. 2004. PMID: 15108350

5

Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study.

Daud A, Valkov N, Centeno B, Derderian J, Sullivan P, Munster P, Urbas P, Deconti RC, Berghorn E, Liu Z, Hausheer F, Sullivan D. Daud A, et al. Clin Cancer Res. 2005 Apr 15;11(8):3009-16. doi: 10.1158/1078-0432.CCR-04-1722. Clin Cancer Res. 2005. PMID: 15837755 Clinical Trial.

6

Valproic acid alters chromatin structure by regulation of chromatin modulation proteins.

Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. Marchion DC, et al. Among authors: daud ai. Cancer Res. 2005 May 1;65(9):3815-22. doi: 10.1158/0008-5472.CAN-04-2478. Cancer Res. 2005. PMID: 15867379

7

In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates.

Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. Marchion DC, et al. Among authors: daud ai. Mol Cancer Ther. 2005 Dec;4(12):1993-2000. doi: 10.1158/1535-7163.MCT-05-0194. Mol Cancer Ther. 2005. PMID: 16373714

8

Evaluation of toxicity following electrically mediated interleukin-12 gene delivery in a B16 mouse melanoma model.

Heller L, Merkler K, Westover J, Cruz Y, Coppola D, Benson K, Daud A, Heller R. Heller L, et al. Clin Cancer Res. 2006 May 15;12(10):3177-83. doi: 10.1158/1078-0432.CCR-05-2727. Clin Cancer Res. 2006. PMID: 16707618

9

Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database.

Khan MA, Andrews S, Ismail-Khan R, Munster PN, Brem S, King J, Reintgen DS, Sondak VK, Daud AI. Khan MA, et al. Among authors: daud ai. Cancer Control. 2006 Jul;13(3):211-7. doi: 10.1177/107327480601300308. Cancer Control. 2006. PMID: 16885917 Free article.

10

Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study.

Simon GR, Garrett CR, Olson SC, Langevin M, Eiseman IA, Mahany JJ, Williams CC, Lush R, Daud A, Munster P, Chiappori A, Fishman M, Bepler G, Lenehan PF, Sullivan DM. Simon GR, et al. Clin Cancer Res. 2006 Aug 1;12(15):4645-51. doi: 10.1158/1078-0432.CCR-05-2379. Clin Cancer Res. 2006. PMID: 16899614 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

204 results

Search Page

Filters